Like Ozempic, Mounjaro is not included in the GLP-1 Bridge program because it carries a diabetes indication rather than a weight-loss indication
Cold Spring Harb Perspect Biol 7:a020412 Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long covid: major findings, mechanisms and recommendations
Reports of several medical emergencies reached Switzerland in this context
Fully medically supervised treatment with personalized GLP-1 dosing plans
Additional information Enhanced Digital Features To view enhanced digital features for this article go to Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made